Last reviewed · How we verify
Helicocerin — Competitive Intelligence Brief
unknown
Coagulation factor XIII A chain, Fatty acid synthase, Pol polyprotein
Hematology
Live · refreshed every 30 min
Target snapshot
Helicocerin (cerulenin). Helicocerin works by inhibiting the activity of coagulation factor XIII A chain, a protein involved in blood clotting.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Helicocerin TARGET | cerulenin | unknown | Coagulation factor XIII A chain, Fatty acid synthase, Pol polyprotein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Helicocerin CI watch — RSS
- Helicocerin CI watch — Atom
- Helicocerin CI watch — JSON
- Helicocerin alone — RSS
Cite this brief
Drug Landscape (2026). Helicocerin — Competitive Intelligence Brief. https://druglandscape.com/ci/cerulenin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing